-
Adoptive immunotherapy of cancer using CD4(+) T cells.
Curr Opin Immunol. 2009 Apr;21(2):200-8
PMID: 19285848
-
Generation of peptide-MHC class I complexes through UV-mediated ligand exchange.
Nat Protoc. 2006;1(3):1120-32
PMID: 17406393
-
Mutant MHC class II epitopes drive therapeutic immune responses to cancer.
Nature. 2015 Apr 30;520(7549):692-6
PMID: 25901682
-
Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions.
Clin Cancer Res. 2014 Jul 1;20(13):3401-10
PMID: 24987109
-
IMGT/V-QUEST: IMGT standardized analysis of the immunoglobulin (IG) and T cell receptor (TR) nucleotide sequences.
Cold Spring Harb Protoc. 2011 Jun;2011(6):695-715
PMID: 21632778
-
Delving into somatic variation in sporadic melanoma.
Pigment Cell Melanoma Res. 2012 Mar;25(2):155-70
PMID: 22260482
-
T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis.
Mol Ther. 2011 Mar;19(3):620-6
PMID: 21157437
-
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
Science. 2015 Apr 3;348(6230):124-8
PMID: 25765070
-
Immune Checkpoint Blockade in Cancer Therapy.
J Clin Oncol. 2015 Jun 10;33(17):1974-82
PMID: 25605845
-
Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer.
Science. 2014 May 9;344(6184):641-5
PMID: 24812403
-
MHC class I-restricted recognition of a melanoma antigen by a human CD4+ tumor infiltrating lymphocyte.
Cancer Res. 1999 Dec 15;59(24):6230-8
PMID: 10626817
-
Design and use of conditional MHC class I ligands.
Nat Med. 2006 Feb;12(2):246-51
PMID: 16462803
-
Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1.
N Engl J Med. 2008 Jun 19;358(25):2698-703
PMID: 18565862
-
Combinatorial tetramer staining and mass cytometry analysis facilitate T-cell epitope mapping and characterization.
Nat Biotechnol. 2013 Jul;31(7):623-9
PMID: 23748502
-
Mutated PPP1R3B is recognized by T cells used to treat a melanoma patient who experienced a durable complete tumor regression.
J Immunol. 2013 Jun 15;190(12):6034-42
PMID: 23690473
-
Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy.
Clin Cancer Res. 2011 Jul 1;17(13):4550-7
PMID: 21498393
-
Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials.
J Immunol Methods. 1987 Aug 24;102(1):127-41
PMID: 3305708
-
Selected murine residues endow human TCR with enhanced tumor recognition.
J Immunol. 2010 Jun 1;184(11):6232-41
PMID: 20427762
-
The cancer antigenome.
EMBO J. 2013 Jan 23;32(2):194-203
PMID: 23258224
-
Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR.
J Immunol. 2005 Nov 1;175(9):5799-808
PMID: 16237072
-
Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response.
Sci Transl Med. 2014 Sep 17;6(254):254ra128
PMID: 25232180
-
Protein kinase inhibitors substantially improve the physical detection of T-cells with peptide-MHC tetramers.
J Immunol Methods. 2009 Jan 1;340(1):11-24
PMID: 18929568
-
Hallmarks of cancer: the next generation.
Cell. 2011 Mar 4;144(5):646-74
PMID: 21376230
-
Incorporation of transmembrane hydrophobic mutations in the TCR enhance its surface expression and T cell functional avidity.
J Immunol. 2012 Jun 1;188(11):5538-46
PMID: 22544927
-
Decade in review-cancer immunotherapy: entering the mainstream of cancer treatment.
Nat Rev Clin Oncol. 2014 Nov;11(11):630-2
PMID: 25311350
-
T-cell epitope prediction methods: an overview.
Methods Mol Biol. 2014;1184:333-64
PMID: 25048134
-
A landscape of driver mutations in melanoma.
Cell. 2012 Jul 20;150(2):251-63
PMID: 22817889
-
Efficient nonviral Sleeping Beauty transposon-based TCR gene transfer to peripheral blood lymphocytes confers antigen-specific antitumor reactivity.
Gene Ther. 2009 Aug;16(8):1042-9
PMID: 19494842
-
High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma.
Nat Med. 2015 Jan;21(1):81-5
PMID: 25531942
-
Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells.
Nat Med. 2013 Jun;19(6):747-52
PMID: 23644516
-
Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones.
Science. 1992 Jul 10;257(5067):238-41
PMID: 1352912
-
Cooperation of human tumor-reactive CD4+ and CD8+ T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR.
Immunity. 2005 Jan;22(1):117-29
PMID: 15664164
-
Properties of MHC class I presented peptides that enhance immunogenicity.
PLoS Comput Biol. 2013 Oct;9(10):e1003266
PMID: 24204222
-
Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing.
Nature. 2014 Nov 27;515(7528):572-6
PMID: 25428506
-
High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation.
Mol Ther. 2006 Jan;13(1):151-9
PMID: 16140584
-
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.
J Clin Oncol. 2005 Apr 1;23(10):2346-57
PMID: 15800326
-
Genetic basis for clinical response to CTLA-4 blockade in melanoma.
N Engl J Med. 2014 Dec 4;371(23):2189-99
PMID: 25409260
-
A ras-mutated peptide targeted by CTL infiltrating a human melanoma lesion.
J Immunol. 2002 May 1;168(9):4802-8
PMID: 11971032
-
Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy.
Nat Rev Cancer. 2014 Feb;14(2):135-46
PMID: 24457417
-
Targeting cancer-specific mutations by T cell receptor gene therapy.
Curr Opin Immunol. 2015 Apr;33:112-9
PMID: 25728991
-
High sensitivity of cancer exome-based CD8 T cell neo-antigen identification.
Oncoimmunology. 2014 May 14;3:e28836
PMID: 25083320
-
CD4(+), HLA class I-restricted, cytolytic T-lymphocyte clone against primary malignant melanoma cells.
Int J Cancer. 2000 Jan 15;85(2):253-9
PMID: 10629086
-
Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma.
J Clin Oncol. 2013 Nov 10;31(32):e439-42
PMID: 24043743
-
Mutational landscape and significance across 12 major cancer types.
Nature. 2013 Oct 17;502(7471):333-9
PMID: 24132290
-
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.
Nature. 2014 Nov 27;515(7528):577-81
PMID: 25428507
-
Immune epitope database analysis resource.
Nucleic Acids Res. 2012 Jul;40(Web Server issue):W525-30
PMID: 22610854
-
Cancer genome landscapes.
Science. 2013 Mar 29;339(6127):1546-58
PMID: 23539594
-
Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1.
Front Immunol. 2014 May 16;5:206
PMID: 24904570
-
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.
Blood. 2009 Jul 16;114(3):535-46
PMID: 19451549
-
Higher throughput methods of identifying T cell epitopes for studying outcomes of altered antigen processing and presentation.
Front Immunol. 2013 Dec 05;4:430
PMID: 24367368